BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 15807221)

  • 1. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
    Lee KL; Couchman GM; Walmer DK
    J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
    Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
    Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.
    Blumenfeld Z; Lang N; Amit A; Kahana L; Yoffe N
    Fertil Steril; 1994 Sep; 62(3):456-60. PubMed ID: 8062938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility.
    Rashidi M; Aaleyasin A; Aghahosseini M; Loloi S; Kokab A; Najmi Z
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):244-7. PubMed ID: 23541417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome.
    Parsanezhad ME; Alborzi S; Pakniat M; Schmidt EH
    Fertil Steril; 2003 Nov; 80(5):1151-5. PubMed ID: 14607566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone.
    Filicori M; Cognigni GE; Pocognoli P; Tabarelli C; Ferlini F; Perri T; Parmegiani L
    Fertil Steril; 2003 Aug; 80(2):390-7. PubMed ID: 12909504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome.
    Isik AZ; Vicdan K
    Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):208-12. PubMed ID: 11451550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antral follicle count predicts the outcome of pregnancy in a controlled ovarian hyperstimulation/intrauterine insemination program.
    Chang MY; Chiang CH; Chiu TH; Hsieh TT; Soong YK
    J Assist Reprod Genet; 1998 Jan; 15(1):12-7. PubMed ID: 9493060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques.
    Martins WP; Vieira AD; Figueiredo JB; Nastri CO
    Cochrane Database Syst Rev; 2013 Mar; (3):CD010042. PubMed ID: 23543584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
    Carone D; Caropreso C; Vitti A; Chiappetta R
    J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration.
    Filicori M; Cognigni GE; Pocognoli P; Tabarelli C; Spettoli D; Taraborrelli S; Ciampaglia W
    Hum Reprod; 2002 Aug; 17(8):2009-15. PubMed ID: 12151429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.